{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:38:08Z","timestamp":1747147088440,"version":"3.40.5"},"reference-count":34,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1TL1TR001443"],"award-info":[{"award-number":["1TL1TR001443"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adjuvant ipilimumab was found to improve the overall survival and reduce toxicity compared to high\u2010dose interferon (HDI) in patients with resected, high\u2010risk melanoma. However, the cost of ipilimumab is substantially higher than HDI. This study evaluates the cost\u2010effectiveness of ipilimumab as an adjuvant treatment in melanoma from a healthcare perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We designed a Markov model simulating resected, high\u2010risk melanoma patients receiving either ipilimumab or HDI. Transition probabilities, including risks of survival, disease progression, and toxicity, were ascertained from clinical trial data. Costs and quality of life measurements (health utilities) were extracted from the literature. Incremental cost\u2010effectiveness ratios (ICERs), defined as incremental costs divided by incremental quality\u2010adjusted life\u2010years (QALYs), assessed cost\u2010effectiveness. ICERs &lt;$100,000\/QALY were deemed cost\u2010effective. We measured model uncertainty with one\u2010way and probabilistic sensitivity analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our base case model, ipilimumab increased costs by $107,100 and increased effectiveness by 0.43 QALY, yielding an ICER of $392,600\/QALY. Our model was moderately sensitive to the costs of ipilimumab, though the cost of ipilimumab would need to decrease by 44% for ipilimumab to become cost\u2010effective compared to HDI. The model was not sensitive to survival, toxicity, or other costs. Probabilistic sensitivity analysis showed that HDI would remain the cost\u2010effective treatment option 96.2% of the time at a willingness\u2010to\u2010pay threshold of $100,000\/QALY.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Adjuvant ipilimumab increases the survival and decreases the toxicity compared to HDI in resected, high\u2010risk melanoma patients, though this would not be considered cost\u2010effective due to the high price of ipilimumab.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4194","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T08:45:18Z","timestamp":1629189918000},"page":"6618-6626","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost\u2010effectiveness of ipilimumab versus high\u2010dose interferon as an adjuvant therapy in resected high\u2010risk melanoma"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5195-5590","authenticated-orcid":false,"given":"Mia","family":"Salans","sequence":"first","affiliation":[{"name":"University of California San Diego School of Medicine La Jolla California USA"},{"name":"Department of Radiation Medicine and Applied Sciences University of California San Diego La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Travis","family":"Courtney","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine La Jolla California USA"},{"name":"Department of Radiation Medicine and Applied Sciences University of California San Diego La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Yip","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine La Jolla California USA"},{"name":"Department of Radiation Medicine and Applied Sciences University of California San Diego La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Murphy","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine La Jolla California USA"},{"name":"Department of Radiation Medicine and Applied Sciences University of California San Diego La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Curiel\u2010LewandrowskiC.Risk factors for the development of melanoma. UpToDate. Published 2020.https:\/\/www.uptodate.com\/contents\/risk\u2010factors\u2010for\u2010the\u2010development\u2010of\u2010melanoma?search=melanomaepidemiology&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed April 14 2020."},{"key":"e_1_2_8_3_1","unstructured":"Surveillance Epidemiology and End Results Program.Cancer Stat facts: melanoma of the skin.https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html. Accessed February 1 2021."},{"volume-title":"NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 4.2020.","year":"2020","key":"e_1_2_8_4_1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01381"},{"key":"e_1_2_8_6_1","unstructured":"Ipilimumab: Drug information. In:PostTW ed.UpToDate.UpToDate;2021.https:\/\/www.uptodate.com\/contents\/ipilimumab\u2010drug\u2010information. Accessed July 15 2021."},{"key":"e_1_2_8_7_1","unstructured":"TreeAge Pro 2021 R1. TreeAge Software.http:\/\/www.treeage.com. Accessed February 1 2021."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"issue":"122","key":"e_1_2_8_9_1","first-page":"1999","article-title":"Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999\u20132000 through 2015\u20132016","volume":"2018","author":"Fryar CD","year":"2018","journal-title":"Natl Health Stat Report"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx226"},{"key":"e_1_2_8_11_1","unstructured":"Surveillance Research Program National Cancer Institute SEER*Stat software version 8.3.9.https:\/\/seer.cancer.gov\/seerstat\/. Accessed February 1 2021."},{"volume-title":"Life Tables for the United States Social Security Area 1900\u20102100","year":"2005","author":"Bell FC","key":"e_1_2_8_12_1"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy193"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.739226"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.05.013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.006"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.2.181"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1138962"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.1007"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1931-3"},{"volume-title":"May 2019 National Occupational Employment Wage Estimates United States.","year":"2019","author":"US Bureau of Labor of Labor Statistics","key":"e_1_2_8_21_1"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00002-1"},{"volume-title":"The Consumer Price Index : Concepts and Content over the Years","year":"1977","author":"United States. Bureau of Labor Statistics","key":"e_1_2_8_23_1"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.6336"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02117-9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-014-0649-6"},{"volume-title":"UpToDate","year":"2021","author":"Post TW","key":"e_1_2_8_27_1"},{"issue":"2","key":"e_1_2_8_28_1","first-page":"184","article-title":"Cost\u2010effectiveness of pembrolizumab versus ipilimumab in ipilimumab\u2010na\u00efve patients with advanced melanoma in the United States","volume":"23","author":"Wang J","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.6.653"},{"key":"e_1_2_8_30_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program.SEER*Stat Database: Incidence \u2010 SEER Research Data 9 Registries Nov 2020 Sub (1975\u20102018) \u2010 Linked To County Attributes \u2010 Time Dependent (1990\u20102018) Income\/Rurality 1969\u20102019 Counties National Cancer Institute DCCPS Surveillance Research Program released April 2021 based on the November 2020 submission.http:\/\/www.seer.cancer.gov\/. Accessed February 1 2021."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0858-3"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz110"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1331432"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.09.045"},{"volume-title":"Cost\u2010Effectiveness Analysis in Health: A Practical Approach","year":"2007","author":"Muenning P","key":"e_1_2_8_35_1"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4194","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4194","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:45:03Z","timestamp":1693295103000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":34,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/cam4.4194"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4194","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"2021-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}